Your Health, We Care
Tepotinib is a P-gp inhibitor. Concomitant use of Tepotinib increases the concentration of P-gp substrates, which may increase the incidence and severity of adverse reactions of these substrates. Avoid concomitant use of Tepotinib with certain P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.
from FDA，2023.03
